{
    "id": "professional_medicine-147",
    "question": "A 55-year-old woman with small cell carcinoma of the lung is admitted to the hospital to undergo chemotherapy. Six days after treatment is started, she develops a temperature of 38\u00b0C (100.4\u00b0F). Physical examination shows no other abnormalities. Laboratory studies show a leukocyte count of 100/mm3 (5% segmented neutrophils and 95% lymphocytes). Which of the following is the most appropriate pharmacotherapy to increase this patient's leukocyte count?",
    "options": {
        "A": "Darbepoetin",
        "B": "Dexamethasone",
        "C": "Filgrastim",
        "D": "Interferon alfa"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To address this question, we need to consider the patient's condition and the laboratory findings. The patient has small cell carcinoma of the lung and has developed a fever, which is a common side effect of chemotherapy. The laboratory studies show a low leukocyte count with a predominance of lymphocytes, indicating a possible immunosuppression. The goal is to increase the leukocyte count to help the patient recover from the fever and potentially reduce the risk of infection. Let's evaluate the options: Option A, Darbepoetin, is an erythropoiesis-stimulating agent used to increase red blood cell production, not white blood cell production. Therefore, it is not the most appropriate choice. Option B, Dexamethasone, is a corticosteroid that can suppress the immune system, which is the opposite of what is needed in this scenario. It can also worsen the patient's infection risk. Option D, Interferon alfa, is an immunomodulatory agent that can increase the production of white blood cells, but it is not the first-line treatment for chemotherapy-induced leukopenia. Option C, Filgrastim, is a granulocyte-colony stimulating factor (G-CSF) that specifically stimulates the production of neutrophils, a type of white blood cell. It is commonly used to reduce the incidence of infection in patients undergoing chemotherapy-induced neutropenia. Given the patient's low neutrophil count and fever, Filgrastim is the most appropriate choice to increase the patient's leukocyte count and reduce the risk of infection. Answer Choice: C\", \"reasoning\": \"The patient's low neutrophil count and fever make it essential to increase the production of these cells to prevent infection. Filgrastim is the most appropriate choice to stimulate neutrophil production, making it the correct answer.\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 53.386290311813354
}